Loading...
PPARγ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
Several drugs approved for a variety of indications have been shown to exhibit antiangiogenic effects. Our study focuses on the PPARγ ligand rosiglitazone, a compound widely used in the treatment of type 2 diabetes. We demonstrate, for the first time to our knowledge, that PPARγ is highly expressed...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Clinical Investigation
2002
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC151148/ https://ncbi.nlm.nih.gov/pubmed/12370270 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI15634 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|